EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioavailability of Oral Ondansetron in Dogs: A Crossover Study

Amanda Garrick iD, Kristin Zersen iD, Daniel Gustafson, Jessica Quimby, Amanda Diaz, Sarah Shropshire

Journal of Veterinary Pharmacology and Therapeutics · 2026-01 · 49 (1) · 17-21

DOI: 10.1111/jvp.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 09.09.2025. Verfasst von Amanda Garrick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Ondansetron, Antiemetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Colorado State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to evaluate the pharmacokinetics of oral (PO) ondansetron compared to intravenous (IV) ondansetron in eight healthy client‐owned dogs. Dogs were randomized to one of two protocols in a crossover design, receiving PO or IV ondansetron at a dose of 1 mg/kg on Day 0 and the opposite formulation at an equal dose on Day 7. Plasma was collected at baseline and 1, 2, 4, and 8 h post administration. Ondansetron concentrations were measured utilizing liquid chromatography/mass spectrometry. For IV administration, AUC 0–8h was 1181 ± 619 ng/mL*h, with all dogs having detectable plasma concentrations at all time points. For PO administration, mean C max was 22 ± 11.3 ng/mL and AUC 0–8h was 61.7 ± 45.4 ng/mL*h, with all dogs having undetectable concentrations at various time points. Oral mean bioavailability was estimated at 5.2% ± 2.1%. Oral bioavailability of ondansetron is very low in healthy dogs, raising concern for the efficacy of ondansetron when given orally at 1 mg/kg. Future studies evaluating pharmacodynamics of ondansetron in nauseous client‐owned dogs should be performed to investigate whether plasma drug concentrations are the optimal way to assess the efficacy of oral ondansetron.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OndansetronAntiemeticsAnimalsDogsCross-Over StudiesAdministration, OralBiological AvailabilityMaleFemaleArea Under CurveHalf-Life

Substanzen

OndansetronAntiemetics

Autor:innen und Institutionen

  • Clinical Sciences Department, Colorado State University, Fort Collins, Colorado, USA.

ORCID-Profile: Amanda Garrick, Kristin Zersen

Förderung

  • Colorado State University

Zitieren

APA

Garrick, A., Zersen, K., Gustafson, D., Quimby, J., Diaz, A., & Shropshire, S. (2026). Bioavailability of Oral Ondansetron in Dogs: A Crossover Study. Journal of Veterinary Pharmacology and Therapeutics, 49(1), 17-21. https://doi.org/10.1111/jvp.70024

Vancouver

Garrick A, Zersen K, Gustafson D, Quimby J, Diaz A, Shropshire S. Bioavailability of Oral Ondansetron in Dogs: A Crossover Study. Journal of Veterinary Pharmacology and Therapeutics. 2026;49(1):17-21. doi:10.1111/jvp.70024

BibTeX
@article{Garrick2026,
  author = {Garrick, Amanda and Zersen, Kristin and Gustafson, Daniel and Quimby, Jessica and Diaz, Amanda and Shropshire, Sarah},
  title = {Bioavailability of Oral Ondansetron in Dogs: A Crossover Study},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2026},
  volume = {49},
  number = {1},
  pages = {17--21},
  doi = {10.1111/jvp.70024}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche